Optimum duration of oral adjuvant chemotherapy of HCFU for colorectal cancer; review of 5-year follow-up.

Ito, K; Kato, T; Koike, A; Miura, K; Yamaguchi, A; Sakou, T; Takagi, H

Ito, K; Kato, T; Koike, A; Miura, K; Yamaguchi, A; Sakou, T; Takagi, H.

Affiliation

Ito K; Department of Surgery II, School of Medicine, Nagoya University, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. katsuki@tsuru.med.nagoya-u.ac.jp

Anticancer Res ; 20(6C): 4681-6, 2000.

Article in En | MEDLINE | ID: mdl-11205200

Subject(s)

Antimetabolites, Antineoplastic/therapeutic use; Colonic Neoplasms/drug therapy; Colonic Neoplasms/surgery; Colorectal Neoplasms/drug therapy; Colorectal Neoplasms/surgery; Fluorouracil/therapeutic use; Rectal Neoplasms/drug therapy; Rectal Neoplasms/surgery; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic/administration & dosage; Colonic Neoplasms/mortality; Colonic Neoplasms/pathology; Colorectal Neoplasms/mortality; Colorectal Neoplasms/pathology; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil/administration & dosage; Follow-Up Studies; Humans; Male; Middle Aged; Rectal Neoplasms/mortality; Rectal Neoplasms/pathology; Retrospective Studies; Survival Rate; Time Factors

Search on Google

XML

PubMed Links

Database: MEDLINE Main subject: Rectal Neoplasms / Colorectal Neoplasms / Colonic Neoplasms / Fluorouracil / Antimetabolites, Antineoplastic Type of study: Observational_studies / Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Year: 2000 Type: Article

Search on Google

XML

PubMed Links